ESC 365 - Milrinone, dobutamine or levosimendan as first line inotrope in cardiogenic shock?

ACVC Premium Access

Milrinone, dobutamine or levosimendan as first line inotrope in cardiogenic shock?

Session: State-of-the-art treatment of cardiogenic shock in 2023

Topic: Acute Heart Failure

Speaker: Professor F. Verbrugge (Brussels, BE)

Event: ESC Acute CardioVascular Care 2023

Congress Presentation

Add to my library

About the speaker

Professor Frederik Hendrik Verbrugge

University Hospital (UZ) Brussels, Brussels (Belgium)

13 presentations

6 followers

3 more presentations in this session

Should the intra-aortic balloon pump be definitively abandoned?

Speaker: Doctor J. Josiassen (Copenhagen, DK)

Combining different types of percutaneous mechanical support to improve outcomes

Speaker: Professor P. Clemmensen (Hamburg, DE)

State-of-the-art treatment of cardiogenic shock in 2023 - discussion

Access the full session

State-of-the-art treatment of cardiogenic shock in 2023

Speakers: Professor F. Verbrugge, Doctor J. Josiassen, Professor P. Clemmensen

About the event

ESC Acute CardioVascular Care 2023

24 March - 26 March 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources